AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00632489
Drug: LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.
Trial: NCT00632489
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be administered orally twice daily for 14 days out of every 21 days.
Trial: NCT00452777
Drug: BVT.115959
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00452777
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03878277
Drug: Starbucks® Cold brew - 325ml bottle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starbucks® Cold brew 325ml bottles daily \[205mg caffeine\] will be provided to the participants. Participants will be instructed to drink 1 bottle every morning between 6 and 9 am for 6 days prior to the post-intervention visit. The 7th day is the post-intervention visit, and participants will be asked to drink 1 bottle the morning of the study visit
Trial: NCT00777868
Drug: Low Strength IDP-108
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application once a day for 9 months
Trial: NCT00777868
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application once a day for 9 months
Trial: NCT04293809
Drug: Exparel Injectable Product
RxNorm normalized name: Exparel Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine liposome injectable suspension
Trial: NCT03208309
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03227484
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily over 8 weeks
Trial: NCT01081782
Drug: ONO-4641 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once per day for 26 weeks
Trial: NCT03297424
Drug: PLX2853
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT00469690
Drug: Acular, Xibrom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Acular 5ml (in the eye)Instill one drop into the eye to be operated on four times a day at (6am, 12pm, 6pm, 12am)~2. Xibrom 5ml (in the eye) Instill one drop into the eye to be operated on two times a day (8am and 8pm)
Trial: NCT00573859
Drug: ADHD medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the ADHD medication condition, participants received their usual dosage of their usual ADHD medication for two consecutive days.
Trial: NCT00573859
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the placebo condition, participants received placebo pills for two consecutive days.
Trial: NCT02260089
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01432587
Drug: Diflunisal
RxNorm normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Film-coated tablet, 250 mg twice daily, orally for approximately 2 years
Trial: NCT01559129
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules taken orally once a day
Trial: NCT01986764
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01986764
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules will be filled with lactose powder.
Trial: NCT00647933
Drug: Lyndiol®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) tablets orally once a day for 6 weeks.
Trial: NCT02623582
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04671966
Drug: Estradiol patch
RxNorm normalized name: Estradiol Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brand name Climara for estrogen add back portion of study. Premenopausal women treated with a GnRH antagonist will be randomized to estrogen add-back or placebo. Thus, for women without contradictions to estrogen use, the risks associated with their use for the duration proposed in these studies (i.e., 6 days) are small. The respective estradiol regimen is a standard approved dose for treatment of hot flashes and the prevention of osteoporosis, and this dose will increase E2 to concentrations typically observed during the mid to late follicular phase of the menstrual cycle.
Trial: NCT02535091
Drug: YKP3089
FDA approved: no
EMA approved: no
PMDA approved: no
Description: see above
Trial: NCT05319912
Drug: ALXN1840 Non-coated Capsule
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.
Trial: NCT03101839
Drug: AZD4785
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KRAS Antisense Oligonucleotide
Trial: NCT03750786
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bevacizumab 5 mg/kg intravenous infusion; Oxaliplatin 85 mg/m2 intravenous infusion; Leucovorin 400 mg/m2 intravenous infusion; 5-FU 400 mg/m2 intravenous infusion; 5-FU 2400 mg/m2 intravenous infusion
Trial: NCT01349660
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BKM120 orally (PO) once daily
Trial: NCT00939562
Drug: doxycycline carragenate tablet
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet, 100 mg, Single dose
Trial: NCT05236907
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patients were assessed using the Memorial Delirium Assessment Scale (MDAS) after the operation at 30, 60, and 90 min. Melatonin was shown to reduce delirium from 41.6% to 16.6% at 60 minutes, and the significant reduction was at 90 minutes (0%) when compared to both groups. Thus, melatonin was found to be successful in decreasing postoperative delirium when administered preoperatively.
Trial: NCT00612560
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill 1 per day
Trial: NCT00506441
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3g to 15g/day (3 times a day), Tablet, 4 weeks of double blind
Trial: NCT02104778
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine 1:200,000 is added to 0.5% ropivacaine 20 ml for sciatic nerve block
Trial: NCT00684723
Drug: Lovastatin 40 mg Tablets
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg tablet administered 30 minutes following the start of a standardized high-fat, high-calorie breakfast
Trial: NCT00684723
Drug: Lovastatin (Mevacor®) 40 mg Tablets
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg tablet administered 30 minutes following the start of a standardized high-fat, high-calorie breakfast
Trial: NCT04276415
Drug: DS-6157a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as a single agent intravenously (IV) every 3 weeks
Trial: NCT00338793
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01815736
Drug: E/C/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150/150/200/10 mg FDC tablet administered orally once daily
Trial: NCT01815736
Drug: E/C/F/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150/150/200/300 mg FDC tablet administered orally once daily
Trial: NCT01815736
Drug: EFV/FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600/200/300 mg FDC tablet administered orally once daily
Trial: NCT01815736
Drug: RTV
RxNorm normalized name: Accu-Chek SmartView Test Strips
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tablet administered orally once daily
Trial: NCT00222872
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug via subcutaneous injection in single blinded fashion daily for 3 weeks
Trial: NCT00242411
Drug: Conventional Best Asthma Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01815736
Drug: FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200/300 mg tablet administered orally once daily
Trial: NCT02729064
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study subjects will receive intranasal placebo (normal saline) via a metered nasal dispenser.
Trial: NCT01905150
Drug: G-FLIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-FLIP is a combination of Low Doses of Gemcitabine, Fluorouracil \[5FU\], Leucovorin, Irinotecan, and Oxaliplatin
Trial: NCT01602029
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
Trial: NCT01602029
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to TAU
Trial: NCT01602029
Drug: Odansetron plus simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron will be administered in 8mg once daily dose and Simvastatin 20mg taken as once daily dose
Trial: NCT02114619
Drug: Intermediate dose
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We will administer 150 micro currie of iodine per thyroid gram
Trial: NCT02114619
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We will administer 200 micro currie of iodine per thyroid gram
Trial: NCT02085395
Drug: SR-T100 ® Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01737307
Drug: CPP-ACP
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CPP-ACP paste was applied by patient, once daily.
Trial: NCT04413344
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: Identical tablets which contain no active ingredient
Trial: NCT00019461
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01209234
Drug: MRSA Decolonization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.
Trial: NCT00646399
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate Buffered Saline on Days 0, 1, 2, 9, 16 and 23.
Trial: NCT02431312
Drug: Nucleos(t)ide Analogue Treatment
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued treatment with nucleos(t)ide analogue
Trial: NCT02314481
Drug: MPDL3280A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion, as monotherapy of in combination with chemotherapy
Trial: NCT04069221
Drug: Single oral dose of 800 mg OZ439
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 800 mg OZ439
Trial: NCT01266824
Drug: Proparacaine Hydrochloride Ophthalmic Solution
RxNorm normalized name: Proparacaine Hydrochloride Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop into each eye once prior to the first set of mydriatic (dilating) eye drops
Trial: NCT00411450
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin. Recommended dosage regimen and administration of FOLFIRI was based on local standard of care, the package insert for each product, and institutional guidelines.
Trial: NCT04069221
Drug: iv infusion of [14C]-OZ439
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-minute 10-mL iv infusion of 100 μg \[14C\]-OZ439
Trial: NCT01589367
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5mg PO daily + Placebo 1 tablet PO 2/day x 1week Letrozole 2.5mg PO daily + Placebo 2 tablet+ 1 tablet PO x 1 week Letrozole 2.5mg PO daily + Placebo 2 tablet PO 2/day x 22 weeks
Trial: NCT01852318
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01882543
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double blind placebo capsule
Trial: NCT03854721
Drug: VAX014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for intravesical infusion, 3.33x10\^10 rBMCs per vial
Trial: NCT01793038
Drug: Aromatase inhibitor (litrezole) plus uFSH arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: literozole tablets 5 mg /day for days 3-7 plus intramuscular injections of uFSH 37.5 IU/day for days 3-12
Trial: NCT02849743
Drug: Placebo (for Syntocinon)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is identical to the Syntocinon formulation with the exception of the active compound, i.e., without oxytocin.
Trial: NCT01759706
Drug: Epidural analgesia with naropin + sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midthoracic epidural analgesia with naropin 0.2 % plus sufentanil 0,5 mcg/mL
Trial: NCT03175081
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient undergo elective laparoscopic sleeve gastrectomy will receive 200mL normal saline to be injected through a catheter along the greater curvature and left subdiaphragmatic region of the stomach at the end of the surgical procedure. After the surgery, the medical doctors or nurses in the ward that is not otherwise involved in this research will assess and record the pain score using visual analog scale (VAS) (0-10). The abdomen and shoulder tip pain intensity will be rated at two, four, six, eight, 24 and 48 hours postoperatively.
Trial: NCT04518618
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Spinal anesthesia will be performed with injection of 2.5 ml which will be composed of 10 mg hyperbaric bupivacaine (2 ml) and 25 ugs fentanyl (0.5 ml)
Trial: NCT04164121
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration was conducted on an empty stomach, and the drug was administered once a day on day 1 and once a day from day 8 to day 17.
Trial: NCT01372358
Drug: CIPRO®XR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited
Trial: NCT00650494
Drug: Valtrex® 1000 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg, single dose fed
Trial: NCT01980680
Drug: Progesterone and Estradiol
RxNorm normalized name: medroxyprogesterone and estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01610037
Drug: QVA149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QVA149 110/50 µg will be supplied as capsules in blister packs for once daily inhalation using the Novartis Concept1 SDDPI
Trial: NCT00462644
Drug: RSI sedation with etomidate/succinylcholine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etomidate 0.3 mg/kg IV plus succinylcholine 1 mg/kg IV
Trial: NCT00462644
Drug: RSI sedation with fentanyl/midazolam/succinylcholine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 micrograms fentanyl IV, plus 5 mg midazolam IV, plus 1 mg/kg succinylcholine IV
Trial: NCT01610037
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to QVA149A and Tiotropium will be supplied in the appropriate capsule in blister packs for use in either the Novartis Concept1 SDDPI or the HandiHaler SDDPI
Trial: NCT00107887
Drug: INH preventive therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinics will receive training regarding the use of IPT for prevention of Tuberculosis
Trial: NCT00107887
Drug: TST (tuberculin skin test)
RxNorm normalized name: TST, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinics will be trained in the use of TST for assessing exposure to TB
Trial: NCT04572828
Drug: 550 mg Naproxen Sodium 60 minutes before the procedure
RxNorm normalized name: naproxen sodium 550 MG
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 550 mg Naproxen Sodium (Abdi Ibrahim, Turkey) will be given to participants in the Group 4, 60 minutes before the procedure.
Trial: NCT02788721
Drug: GLPG2451 single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG2451 oral suspension, single ascending doses, daily
Trial: NCT02788721
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, oral suspension, daily
Trial: NCT03124160
Drug: Mona Lisa® NT Cu380 Mini
FDA approved: no
EMA approved: no
PMDA approved: no
Description: copper intrauterine device
Trial: NCT03124160
Drug: ParaGard® TCu380A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: copper intrauterine device
Trial: NCT04458805
Drug: NX-13 250 mg
RxNorm normalized name: Replesta NX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation in Part A will be conducted in a total of 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and will be randomized to receive either NX-13 or placebo (ratio 5:2). NX-13 will be administered to Cohort 1 participants at the starting dose of 250 mg. The NX-13 dose will be increased in each new cohort. Five nominal dose levels in the range of 250 to 4000 mg have been selected for evaluation in Part A.~It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either NX-13 or placebo (ratio 5:2), once daily for seven days.
Trial: NCT04458805
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation in Part A will be conducted in a total of 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and will be randomized to receive either NX-13 or placebo (ratio 5:2). NX-13 will be administered to Cohort 1 participants at the starting dose of 250 mg. The NX-13 dose will be increased in each new cohort. Five nominal dose levels in the range of 250 to 4000 mg have been selected for evaluation in Part A.~It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either NX-13 or placebo (ratio 5:2), once daily for seven days.
Trial: NCT00953888
Drug: AZD5069
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of oral solution.
Trial: NCT00953888
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of oral solution.
Trial: NCT01287793
Drug: tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous, 200 mg, single dose
Trial: NCT01287793
Drug: tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous, 50 mg, single dose
Trial: NCT01287793
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Sodium Chloride intravenous 100mL, single dose
Trial: NCT04157686
Drug: MT10109L Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT10109L Dose 2 will be injected into the LCL area
Trial: NCT00324974
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole placebo-matching suspension, orally, once daily for up to 28 days.
Trial: NCT04157686
Drug: MT10109L Dose 1 + Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT10109L Dose 1 will be injected into the GL area plus MT10109L Dose 2 will be injected into the LCL area
Trial: NCT00371189
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline.
Trial: NCT03619447
Drug: serratus block group
RxNorm normalized name: Fucus serratus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USG guided serratus plane block will perform bilaterally
Trial: NCT03489343
Drug: Sym023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.
Trial: NCT02517957
Drug: Mullite ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applies to a blister, pustule, erosion, ulcer, leaking or comorbid folliculitis, in skin lesions of 2 times a day, 5 days for one period of treatment, but for two consecutive period of treatment
Trial: NCT00402792
Drug: Hydrocodone/Acetaminophen Extended-Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet q 12 hours
Trial: NCT00402792
Drug: Hydrocodone/Acetaminophen Extended Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets q 12 hours
Trial: NCT00402792
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets q 12 hours
Trial: NCT00128102
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorinostat-matching placebo oral capsules
Trial: NCT01945346
Drug: PRX167700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT01945346
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT00201344
Drug: Cisplatin,5-FU,Leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no